$MBIO News
Last published 10mo ago
- 10mo agoMBIOFFord expands Bronco SUV performance lineup with 'more attainable' RTR modelCNBCFord Motor is expanding its Bronco SUV lineup to include a new model that the automaker is touting as a mix of off-road capabilities and street performance.
- 1y agoAZNCRDFMBIOONCY+1Global Oncology Breakthroughs Being Fueled by Advancements in Clinical Trials and New TherapiesGlobeNewswirePALM BEACH, Fla., July 08, 2025 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The global oncology market, including breakthrough treatments, is experiencing substantial growth, with revenues projected to
- 1y agoFBIOMBIOMustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-101 (IL13Ra2-targeted CAR T-cells) to Treat Astrocytomas and GlioblastomaGlobeNewswireIn an ongoing Phase 1 trial published in Nature Medicine, MB-101 was well-tolerated and 50% of patients achieved stable disease or better with two partial responses and two complete responses lasting 7.5 and 66+ months,
- 1y agoFBIOMBIOMustang Bio Regains Compliance with Nasdaq Capital Market RequirementGlobeNewswireWALTHAM, Mass., March 05, 2025 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. ("Mustang" or the "Company") (NASDAQ:MBIO) today announced that it has received notice from The Nasdaq Stock Market LLC ("Nasdaq") informing the
- 1y agoFBIOMBIOMustang Bio Announces Sale of Fixed Assets and Exit of FacilityGlobeNewswireWALTHAM, Mass., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. ("Mustang" or the "Company") (NASDAQ:MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell
- 1y agoFBIOMBIOMustang Bio Regains Compliance with Nasdaq Minimum Bid Price RequirementGlobeNewswireWORCESTER, Mass., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. ("Mustang" or the "Company") (NASDAQ:MBIO) today announced that it has received notice from The Nasdaq Stock Market LLC ("Nasdaq") informing the
- 1y agoFBIOMBIOMustang Bio Announces Closing of $8 Million Public OfferingGlobeNewswireWORCESTER, Mass., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. ("Mustang" or the "Company") (NASDAQ:MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell
- 1y agoFBIOMBIOMustang Bio Announces Pricing of $8 Million Public OfferingGlobeNewswireWORCESTER, Mass., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. ("Mustang" or the "Company") (NASDAQ:MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell
- 1y agoFBIOMBIOMustang Bio Announces Reverse Stock SplitGlobeNewswireWORCESTER, Mass., Jan. 14, 2025 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. ("Mustang" or the "Company") (NASDAQ:MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell
- 2y agoFBIOMBIOMustang Bio Receives Positive Listing Determination from NasdaqGlobeNewswireWORCESTER, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. ("Mustang" or the "Company") (NASDAQ:MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell
- 2y agoFBIOMBIOMustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-108 (HSV-1 oncolytic virus) to Treat Malignant GliomaGlobeNewswireMB-108 (HSV-1 oncolytic virus) is active and well tolerated in patients with recurrent glioblastoma in ongoing Phase 1 clinical trial Preclinical data support a novel combination of MB-108 (HSV-1 oncolytic virus) and
- 2y agoFBIOMBIOMustang Bio Announces Exercise of Warrants for $4 Million Gross ProceedsGlobeNewswireWORCESTER, Mass., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. ("Mustang" or the "Company") (NASDAQ:MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell
- 2y agoFBIOMBIOMustang Bio Announces Closing of $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesGlobeNewswireWORCESTER, Mass., June 21, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. ("Mustang" or the "Company") (NASDAQ:MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell
- 2y agoONCYMBIOLEGNJNJ+1Biotech Advances Propel Oncology Market to $564.5B Amid Youth Cancer SpikePR NewswireUSA News Group News Commentary – The potential threat of cancer looms for everyone, but now new studies are revealing an increased number of cancer...
- 2y agoFBIOMBIOMustang Bio Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesGlobeNewswireWORCESTER, Mass., June 20, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. ("Mustang" or the "Company") (NASDAQ:MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell
- 2y agoFBIOMBIOMustang Bio Announces Favorable Efficacy and Safety Data from Complete Waldenstrom Macroglobulinemia Cohort of Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR-T TherapyGlobeNewswireOverall response rate of 90% in cohort with durable responses observed; one patient remains in complete remission at 31 months All patients were heavily pretreated/refractory to BTK inhibitors, and only one patient
- 2y agoFBIOMBIOMustang Bio Announces Closing of $4 Million Public OfferingGlobeNewswireWORCESTER, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. ("Mustang" or the "Company") (NASDAQ:MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell
- 2y agoFBIOMBIOMustang Bio Announces Pricing of $4 Million Public OfferingGlobeNewswireWORCESTER, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. ("Mustang" or the "Company") (NASDAQ:MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell
- 2y agoCKPTDERMFBIOMBIOFortress Biotech Reports 2023 Financial Results and Recent Corporate HighlightsGlobeNewswireRecord consolidated net revenue of $84.5 million for full-year 2023 Fortress may receive up to four regulatory decisions on NDAs and BLAs in the next 18 months FDA accepted New Drug Application filing for DFD-29 to
- 2y agoFBIOMBIOMustang Bio Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune DiseasesGlobeNewswirePlanning for proof-of concept Phase 1 investigator-sponsored clinical trial evaluating MB-106 CD20-targeted CAR T-cell therapy in autoimmune diseases is underway and expected to initiate in the fourth quarter of 2024
- 2y agoFBIOMBIOMustang Bio Reports Full-Year 2023 Financial Results and Recent Corporate HighlightsGlobeNewswireWORCESTER, Mass., March 11, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. ("Mustang" or the "Company") (NASDAQ:MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell
- 2y agoFBIOMBIOMustang Bio Announces Publication in Nature Medicine of Data from Phase 1 Trial Evaluating MB-101 IL13Rα2-targeted CAR T-Cells in High-Grade GliomaGlobeNewswireMB-101 was well-tolerated and 50% of patients achieved stable disease or better with two partial responses and two complete responses lasting 7.5 and 66+ months, respectively ~70% improvement in median overall survival
- 2y agoFBIOMBIOCity of Hope-developed Chimeric Antigen Receptor (CAR) T Cell Therapy Shows Clinical Activity in Patients With Aggressive Brain Tumors in a Phase 1 TrialBusiness WireHalf of the enrolled patients had stable disease for at least two months, two showed partial response and two experienced complete response Nature Medicine paper highlights delivery of CAR T cell therapy directly to
- 2y agoFBIOMBIOMustang Bio to Participate in the B. Riley Securities 4th Annual Oncology ConferenceGlobeNewswireWORCESTER, Mass., Jan. 11, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. ("Mustang" or the "Company") (NASDAQ:MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell
- 2y agoFBIOMBIOMustang Bio Presents Updated Phase 1/2 Multicenter Clinical Data for MB-106 at the 2023 American Society of Hematology (ASH) Annual MeetingGlobeNewswireData showed favorable safety profile, complete response rate and durability in the treatment of patients with relapsed or refractory indolent B-cell Non-Hodgkin Lymphoma 100% of patients with follicular lymphoma
- 2y agoFBIOMBIOMustang Bio Reports Third Quarter 2023 Financial Results and Recent Corporate HighlightsGlobeNewswireWORCESTER, Mass., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. ("Mustang") (NASDAQ:MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene
- 3y agoFBIOMBIOMustang Bio Announces MB-106 CD20-Targeted CAR-T Data Selected for Presentation at 65th American Society of Hematology (ASH) Annual MeetingGlobeNewswireWORCESTER, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. ("Mustang") (NASDAQ:MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene
- 3y agoFBIOMBIOMustang Bio Announces Closing of $4.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesGlobeNewswireWORCESTER, Mass., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. ("Mustang" or the "Company") (NASDAQ:MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell
- 3y agoFBIOMBIOMustang Bio Announces $4.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesGlobeNewswireWORCESTER, Mass., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. ("Mustang" or the "Company") (NASDAQ:MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell
- 3y agoFBIOMBIOMustang Bio Announces FDA Acceptance of IND Application for MB-109, a Novel Combination of MB-101 (IL13Rα2‐targeted CAR-T cell therapy) and MB-108 (HSV-1 oncolytic virus), for the Treatment of Recurrent Glioblastoma and High-Grade AstrocytomaGlobeNewswireMB‐101 (IL13Rα2‐targeted CAR-T cell therapy) and MB-108 (HSV-1 oncolytic virus) are separately well tolerated in patients with recurrent GBM in ongoing Phase 1 clinical trials; preclinical data support potential of
- 3y agoFBIOMBIOMustang Bio to Participate in Upcoming September 2023 Investor ConferencesGlobeNewswireWORCESTER, Mass., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. ("Mustang") (NASDAQ:MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene
- 3y agoFBIOMBIOMustang Bio Announces First Data from Ongoing Multicenter Phase 1/2 Clinical Trial Evaluating MB-106 CAR-T Cell TherapyGlobeNewswireInitial data show clinical responses from four of four indolent lymphoma patients, including complete response in follicular lymphoma patient previously treated with CD19 CAR-T cell therapy Aligns with ongoing results
- 3y agoFBIOMBIOMustang Bio Reports Second Quarter 2023 Financial Results and Recent Corporate HighlightsGlobeNewswireWORCESTER, Mass., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. ("Mustang") (NASDAQ:MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene
- 3y agoATXICKPTDERMFBIO+1Fortress Biotech Reports Second Quarter 2023 Financial Results and Recent Corporate HighlightsGlobeNewswireTotal net revenue was $17.4 million in the second quarter of 2023, a 40% increase from $12.4 million in the first quarter of 2023 Positive topline results from two Phase 3 clinical trials evaluating DFD-29
- 3y agoFBIOMBIOMustang Bio to Participate in Two August 2023 Investor ConferencesGlobeNewswireWORCESTER, Mass., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. ("Mustang") (NASDAQ:MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene
- 3y agoFBIOMBIOMustang Bio Announces Amendment and Closing of Strategic Manufacturing Partnership Transaction with uBriGene (Boston) BiosciencesGlobeNewswireWORCESTER, Mass., July 31, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. ("Mustang" or the "Company") (NASDAQ:MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell
- 3y agoMBIORWAYRunway Growth Finance Corp. Provides Second Quarter 2023 Portfolio UpdateGlobeNewswireWOODSIDE, Calif., July 11, 2023 (GLOBE NEWSWIRE) -- Runway Growth Finance Corp. (NASDAQ:RWAY) ("Runway Growth" or the "Company"), a leading provider of flexible capital solutions to late- and growth-stage companies
- 3y agoFBIOMBIOMustang Bio Announces Participation in Upcoming Scientific MeetingsGlobeNewswireWORCESTER, Mass., July 06, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. ("Mustang" or the "Company") (NASDAQ:MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell
- 3y agoFBIOMBIOMustang Bio Announces Final Results from Follicular Lymphoma Cohort of Single-Institution Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR T TherapyGlobeNewswire10 out of 20 patients remain in complete remission for more than a year 95% overall response rate (ORR) and 80% complete response (CR) rate across all patients; 100% ORR and 91% CR with higher dose levels, including one
- 3y agoFBIOMBIOMustang Bio Announces Updated Results from Waldenstrom Macroglobulinemia Cohort of Ongoing Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR T TherapyGlobeNewswireMB-106 continues to demonstrate favorable safety and efficacy profile Overall response rate of 83% in cohort with durable responses observed; one patient remains in complete remission at 22 months All patients were
- 3y agoFBIOMBIOMustang Bio Announces Strategic Manufacturing Partnership and Portfolio UpdatesGlobeNewswireuBriGene (Boston) Biosciences to acquire Mustang Bio's Worcester manufacturing facility for total consideration of up to $11 million and enters into strategic manufacturing partnership to support MB-106 and future
- 3y agoATXICKPTDERMFBIO+1Fortress Biotech Reports First Quarter 2023 Financial Results and Recent Corporate HighlightsGlobeNewswireFortress is advancing several late-stage clinical assets with two NDA submissions anticipated in second half of 2023 PDUFA goal date of January 3, 2024 set by FDA for cosibelimab to treat metastatic or locally advanced
- 3y agoFBIOMBIOMustang Bio Reports First Quarter 2023 Financial Results and Recent Corporate HighlightsGlobeNewswireWORCESTER, Mass., May 12, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. ("Mustang") (NASDAQ:MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapies
- 3y agoFBIOMBIOMustang Bio Announces Upcoming Presentations of Clinical Data from Phase 1/2 Trial of MB-106, a CD20-Targeted Autologous CAR T Cell TherapyGlobeNewswireData from Waldenstrom macroglobulinemia cohort selected for poster presentation at EHA2023 Outpatient treatment of follicular lymphoma selected for oral presentation at ICML WORCESTER, Mass., May 11, 2023 (GLOBE
- 3y agoFBIOMBIOMustang Bio Announces Reverse Stock SplitGlobeNewswireWORCESTER, Mass., April 03, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. ("Mustang" or the "Company") (NASDAQ:MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell
- 3y agoATXICKPTDERMFBIO+1Fortress Biotech Reports Record 2022 Financial Results and Recent Corporate HighlightsGlobeNewswireFortress expects to file a total of three new drug applications in 2023 Record consolidated net revenue of $75.7 million for full-year 2022 FDA accepted for filing the Biologics License Application for cosibelimab in
- 3y agoFBIOMBIOMustang Bio Reports Full-Year 2022 Financial Results and Recent Corporate HighlightsGlobeNewswireWORCESTER, Mass., March 29, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. ("Mustang") (NASDAQ:MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene
- 3y agoFBIOMBIOMustang Bio to Participate in Cantor's The Future of Oncology Virtual SymposiumGlobeNewswireWORCESTER, Mass., March 28, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. ("Mustang" or the "Company") (NASDAQ:MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell
- 3y agoFBIOMBIOMustang Bio to Participate in the B. Riley Securities' 3rd Annual Oncology ConferenceGlobeNewswireWORCESTER, Mass., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. ("Mustang" or the "Company") (NASDAQ:MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell
- 3y agoFBIOMBIOMustang Bio Provides CAR T Cell Therapy Portfolio Updates and 2023 Anticipated MilestonesGlobeNewswireMB-106 clinical trial under Mustang's IND continues to enroll patients Additional IND filing and published research expected in 2023 across portfolio WORCESTER, Mass., Dec. 19, 2022 (GLOBE NEWSWIRE) -- Mustang Bio,